Empowering you to meet regulatory and best practice requirements
Empowering you to meet regulatory and best practice requirements
Patient Safety First |
This month’s Patient Safety Champions’ letter focuses on the impact of distractions on patient safety. This is reflected in this month’s handout scenario.
Please use this scenario, which will be led by your Patient Safety Champion, to reflect on the impact that being distracted during a task can have and how, by managing distractions effectively, you can help to mitigate risk and promote patient safety.
Please share with your Patient Safety Champion any insights or ideas for SMART-ER action(s) you may have in relation to managing distractions to support patient safety in your pharmacy.
IMPORTANT: Reporting adverse events and special situations with Boots-branded licensed medicines and medical devices |
You will be aware that the Company has a legal responsibility to collect and report adverse events (including special situations) and quality issues associated with Boots-branded licensed medicines and medical devices.
Special situation reports provide valuable information about a medical product. A special situation may, or may not, occur in association with an adverse event or medical condition.
But what are ‘special situations’? Types of special situations include:
- Lack of drug effect and drug interactions
- Overdose
- Misuse
- Off label use
- Abuse of a product and medication error
- Use in pregnancy and breastfeeding
- Use in the paediatric and elderly population
- Occupational exposure
- Any suspected transmission of an infectious agent
- Unintended beneficial effect
- Adverse events relating to counterfeit medicinal products.
For further information, including how and when to report adverse events, special situations and quality issues using the MyHub Mission, please visit BootsLive.
IMPORTANT: MHRA Drug Safety Update: Isotretinoin |
The monthly Drug Safety Update issued by the Medicines and Healthcare products Regulatory Agency (MHRA) in October announced the introduction of new safety measures for healthcare professionals involved in the prescribing or dispensing of isotretinoin. These new safety measures have been developed to strengthen the safe use of isotretinoin.
Please review these new measures and ensure that those relevant to community pharmacy are adopted accordingly. The full MHRA update, which includes advice for healthcare professionals and supporting materials, is available on BootsLive.
IMPORTANT: Dosing of Tresiba® FlexTouch® pens |
The long-acting basal insulin (insulin degludec) is available in two strengths as a pre-filled pen in the UK: Tresiba® 100 units/ml FlexTouch® Pen (which delivers insulin in steps of 1 unit, with a maximum of 80 units per injection); and Tresiba® 200 units/ml FlexTouch® Pen (which delivers insulin in steps of 2 units, with a maximum of 160 units per injection).
It is important to note that the dose that is shown in the dose counter window of the pre-filled pen is the number of units that will be provided in the dose, regardless of the strength of the pen. Therefore, if a patient is transferred from one strength of Tresiba® FlexTouch® Pen to another, no dose conversion is needed.
Risk minimisation materials for Tresiba® FlexTouch® Pens are available on BootsLive.